A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors

Trial Profile

A Phase I/II clinical trial evaluating DCVax-Direct, autologous activated dendritic cells for intratumoral injection, in patients with solid tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Dendritic cell vaccine-Northwest Biotherapeutics (Primary)
  • Indications Colorectal cancer; Liver cancer; Malignant melanoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Northwest Biotherapeutics
  • Most Recent Events

    • 01 Sep 2017 According to a Northwest Biotherapeutics media release, an update from this trial will be presented at the Cambridge Healthtech Institute's Immuno-Oncology Summit.
    • 05 Jun 2017 According to a Northwest Biotherapeutics media release, updates on this trial were presented at the ASCO Conference.
    • 29 Sep 2016 According to a Northwest Biotherapeutics media release, data from phase I portion of the trial will be presented in a poster presentation at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top